An ongoing dialogue on HIV/AIDS, infectious diseases,
January 13th, 2009
Can We Have “Too Many Options?”
As part of our regular series “Antiretroviral Rounds” in AIDS Clinical Care, today we post a case of a highly treatment-experienced patient with dreaded “triple class” resistance — that is, resistance to NRTIs, NNRTIs, and PIs.
The good news now, of course, is that we have more than these three drug classes.
The tough part is choosing what to use, as often with so many new options we’re designing regimens that have not been extensively tested in prospective studies. (Or tested at all — for example, no patient in the maraviroc MOTIVATE studies received darunavir; today I’d suspect nearly every patient on this drug is on darunavir.)
We asked three highly-experienced HIV specialists what they’d do for a patient like this with “too many options” — raltegravir-naive, R5 tropic virus, susceptibility to both etravirine and darunavir — and perhaps not surprisingly, we got three different answers.
Further input to management of this case is welcome, of course.
Categories: Antiretroviral Rounds, HIV, Patient Care
Tags: darunavir, etravirine, HIV, maraviroc, raltegravir, resistance
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.
Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- The Rise and Fall of Paxlovid
- Think Again Before Sending Your Patient Home on Intravenous Vancomycin
- Hey, Insurance Companies and Pharmacies — Stop Messing Around with the Price of Cheap Generic Drugs
- CROI 2024 Denver: Really Rapid Review
- Learning the Names of HIV Drugs Is Horribly Difficult — Here’s Why
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
-
NEJM Journal Watch — Recent Infectious Disease Articles
- Next-Generation Antibiotics for Gram-Negative Infections: An Untapped Resource?
- How Accurate Is Screening at ICU Admission and Discharge for Assessing Acquisition of Multidrug-Resistant Organisms?
- Following Patients from Hospital to Home to Clinic: Strategies for Better HIV Outcomes
- Observations from ID and Beyond: Hey, Insurance Companies and Pharmacies — Stop Messing Around with the Price of Cheap Generic Drugs
- Stratifying Antibiotic Timing According to the Surviving Sepsis Campaign Seems Reasonable
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster